A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18–49 year old patients

•Immunocompromised patients are at increased risk for herpes zoster (HZ) and its complications.•The recombinant zoster vaccine (RZV) is indicated for prevention of HZ in adults aged ≥ 50 years.•Consolidated data show RZV has an acceptable safety profile in ≥ 18 y.o. immunocompromised patients.•No ex...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2020-09, Vol.38 (40), p.6205-6214
Main Authors: Racine, Étienne, Gilca, Vladimir, Amini, Rachid, Tunis, Matthew, Ismail, Shainoor, Sauvageau, Chantal
Format: Article
Language:English
Subjects:
Adolescent
Adult
Adults
Age
Chicken pox
Clinical trials
Hematopoietic stem cells
Herpes Zoster
Herpes Zoster - prevention & control
Herpes Zoster Vaccine - adverse effects
Herpesvirus 3, Human
Humans
Immune response
Immune response (cell-mediated)
Immune response (humoral)
Immune system
Immunity
Immunization
Immunocompromised Host
Immunocompromised hosts
Immunogenicity
Immunosuppression
Infections
Literature reviews
Middle Aged
Pain
Safety
Stem cells
Systematic review
Vaccination
Vaccine efficacy
Vaccines
Vaccines, Synthetic - adverse effects
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Immunocompromised patients are at increased risk for herpes zoster (HZ) and its complications.•The recombinant zoster vaccine (RZV) is indicated for prevention of HZ in adults aged ≥ 50 years.•Consolidated data show RZV has an acceptable safety profile in ≥ 18 y.o. immunocompromised patients.•No exacerbation of underlying diseases was observed in RZV groups’ as compared to placebo.•RZV efficacy against HZ in immunocompromised ≥ 18 y.o. patients varied between 67 and 87% The adjuvanted recombinant zoster vaccine (RZV) is indicated for prevention of herpes zoster (HZ) in adults aged ≥50 years. Questions regarding the use of RZV in immunocompromised patients 
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2020.07.049